<DOC>
	<DOC>NCT00401674</DOC>
	<brief_summary>The purpose of this study is to evaluate the toxicity and activity of weekly administration of carboplatin and paclitaxel as first-line chemotherapy for elderly patients with ovarian cancer stage IC-IV.</brief_summary>
	<brief_title>MITO-5: Weekly Carboplatin and Paclitaxel as First Line Chemotherapy for Elderly Patients With Ovarian Cancer</brief_title>
	<detailed_description>This is a phase II multicenter study. The experimental treatment is carboplatin (AUC 2) and paclitaxel 60 mg/m2, on days 1, 8 and 15 every 28 days.</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Age 70 years or greater Cytologic / histologic diagnosis ovarian cancer Stage of disease at diagnosis IC IV Performance status (ECOG) &lt; 3 Indication for chemotherapy treatment Written informed consent Previous or concomitant malignant neoplasia (not including basocellular or spinocellular skin carcinoma or insitu carcinoma of the uterine cervix, provided they are being adequately treated) Cerebral metastases Neutrophils &lt; 1000/mm3, platelets &lt; 100000/mm3, hemoglobin &lt; 8g/dl Creatinine &gt; o = 1.25 times the upper normal limit GOT or GPT &gt; o = 1.25 times the upper normal limit, except in case of liver metastases) Patient's inability to comply with followup</criteria>
	<gender>Female</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>elderly</keyword>
	<keyword>weekly chemotherapy</keyword>
	<keyword>first-line</keyword>
</DOC>